Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:5299
Name endometrial clear cell adenocarcinoma
Definition An endometrial adenocarcinoma that is characterized by the presence of cells with clear cytoplasm.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma endometrial adenocarcinoma endometrial clear cell adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ATM I2629fs ATM neg Elimusertib endometrial clear cell adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00492778 Phase II Cisplatin Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Active, not recruiting USA | CAN 0
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT02065687 Phase III Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Unknown status USA 0
NCT03120624 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Active, not recruiting USA 0
NCT03694262 Phase II Atezolizumab + Bevacizumab + Rucaparib The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) Completed USA 0
NCT03694834 Phase I Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer Terminated USA 0
NCT03914612 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting USA | CAN 3
NCT04065269 Phase II Ceralasertib + Olaparib Ceralasertib ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) Recruiting GBR | CAN 0
NCT04159155 Phase II Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP) Recruiting CAN 0
NCT04196257 Phase I BP1001-A BP1001-A + Paclitaxel BP1001-A in Patients With Advanced or Recurrent Solid Tumors Unknown status USA 0
NCT04197219 Phase II Axitinib + Pembrolizumab Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Withdrawn 0
NCT04719273 Phase II Anastrozole + Onapristone Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer Active, not recruiting USA 0
NCT04750941 Phase II Copanlisib Study of Copanlisib and Ketogenic Diet Active, not recruiting USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT05032040 Phase II XmAb20717 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Recruiting USA 0
NCT05255653 Phase II Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) Recruiting NLD | GBR | FRA | CAN 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Active, not recruiting USA 0
NCT05498597 Phase I AMT-151 AMT-151 in Patients With Selected Advanced Solid Tumours Recruiting AUS 1
NCT05542407 Phase I Atezolizumab + ONC201 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer Recruiting USA 0
NCT05603910 Phase I Lenvatinib + Pembrolizumab Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma Recruiting USA 0
NCT05920798 Phase Ib/II FR alpha peptide vaccine + Pembrolizumab A Study of FRaDCs for Ovarian Cancer Recruiting USA 0
NCT06457997 Phase I PHN-010 A Study of PHN-010 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0